HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.
Commentary|Articles|March 27, 2026
CDC Opioid Guidelines at 10: Impact, Misuse, and Lessons: Michael Lynch, MD
Author(s)Sabrina McCrear, Michael Lynch, MD
Fact checked by: Maggie L. Shaw
A decade after the CDC opioid guidelines, Michael Lynch, MD, examines misapplication, fentanyl’s role, and evolving pain management strategies.
Advertisement
Advertisement
The CDC’s Clinical Practice Guidelines for Prescribing Opioids for Pain are
Related to this article
Erythema-based criteria miss skin of color, urging ROSCO phenotyping to improve diagnostic equity in dermatology.
PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.
Bipolar disorder often goes undiagnosed for years, and clinicians need to separate mood episodes from normal emotions and keep patients on treatment.
Norah Terrault, MD, MPH, on why few diagnosed patients reach HCV cure and how primary care test-and-treat can close the gap.
Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.
HHS enforcement discretion lets state pharmacies compound BPC-157 and other peptides amid rulemaking and legal challenges.
Early modeling put sickle cell gene therapy coverage near 11 cents per member per month.
Advertisement
Advertisement